Log In
Print
BCIQ
Print
Print this Print this
 

Juvisync, sitagliptin/simvastatin

Also known as: MK-0431D

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionFixed-dose combination of simvastatin and sitagliptin
Molecular Target HMG-CoA reductase ; Dipeptidyl peptidase-4 (DPP-4) (CD26)
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today